Pacific Biosciences Has 'Long Road' Ahead, But Cantor Still Bullish
October 01, 2015 at 14:23 PM EDT
Cantor Fitzgerald reiterated a Buy rating and $9.00 price target on shares of Pacific Biosciences of California (NASDAQ: PACB) on ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.